NCT03333616 2026-01-21Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer InstitutePhase 2 Active not recruiting100 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled